Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
International Journal of Molecular Medicine
Join Editorial Board Propose a Special Issue
Print ISSN: 1107-3756 Online ISSN: 1791-244X
Journal Cover
July-2014 Volume 34 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
July-2014 Volume 34 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Astragaloside IV prevents damage to human mesangial cells through the inhibition of the NADPH oxidase/ROS/Akt/NF‑κB pathway under high glucose conditions

  • Authors:
    • Li Sun
    • Weiping Li
    • Weizu Li
    • Li Xiong
    • Guiping Li
    • Rong Ma
  • View Affiliations / Copyright

    Affiliations: Department of Pharmacology, College of Basic Medicine, Anhui Medical University, Hefei, Anhui 230032, P.R. China, Department of Integrative Physiology and Cardiovascular Research Institute, University of North Texas Health Science Center, Fort Worth, TX 76107, USA
  • Pages: 167-176
    |
    Published online on: April 9, 2014
       https://doi.org/10.3892/ijmm.2014.1741
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Glomerular hypertrophy and hyperfiltration are the two major pathological characteristics of the early stages of diabetic nephropathy (DN), which are respectively related to mesangial cell (MC) proliferation and a decrease in calcium influx conducted by canonical transient receptor potential cation channel 6 (TRPC6). The marked increase in the production of reactive oxygen species (ROS) induced by hyperglycemia is the main sponsor of multiple pathological pathways in DN. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is an important source of ROS production in MCs. Astragaloside IV (AS‑IV) is an active ingredient of Radix Astragali which has a potent antioxidative effect. In this study, we aimed to investigate whether high glucose (HG)‑induced NADPH oxidase activation and ROS production contribute to MC proliferation and the downregulation of TRPC6 expression; we also wished to determine the effects of AS‑IV on MCs under HG conditions. Using a human glomerular mesangial cell line, we found that treatment with AS‑IV for 48 h markedly attenuated HG‑induced proliferation and the hypertrophy of MCs in a dose‑dependent manner. The intracellular ROS level was also markedly reduced following treatment with AS‑IV. In addition, the enhanced activity of NADPH oxidase and the expression level of NADPH oxidase 4 (Nox4) protein were decreased. Treatment with AS‑IV also inhibited the phosphorylation level of Akt and IκBα in the MCs. In addition, TRPC6 protein expression and the intracellular free calcium concentration were also markedly reduced following treatment with AS‑IV under HG conditions. These results suggest that AS‑IV inhibits HG‑induced mesangial cell proliferation and glomerular contractile dysfunction through the NADPH oxidase/ROS/Akt/nuclear factor‑κB (NF‑κB) pathway, providing a new perspective for the clinical treatment of DN.
View Figures

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

View References

1 

Parving HH: Diabetic nephropathy: prevention and treatment. Kidney Int. 60:2041–2055. 2001. View Article : Google Scholar : PubMed/NCBI

2 

Bank N: Mechanisms of diabetic hyperfiltration. Kidney Int. 40:792–807. 1991. View Article : Google Scholar

3 

Wei P, Lane PH, Lane JT, Padanilam BJ and Sansom SC: Glomerular structural and functional changes in a high-fat diet mouse model of early-stage Type 2 diabetes. Diabetologia. 47:1541–1549. 2004. View Article : Google Scholar : PubMed/NCBI

4 

Schlöndorff D and Banas B: The mesangial cell revisited: no cell is an island. J Am Soc Nephrol. 20:1179–1187. 2009.PubMed/NCBI

5 

Menè P, Pugliese G, Pricci F, Di Mario U, Cinotti GA and Pugliese F: High glucose level inhibits capacitative Ca2+ influx in cultured rat mesangial cells by a protein kinase C-dependent mechanism. Diabetologia. 40:521–527. 1997.PubMed/NCBI

6 

Nutt LK and O’Neil RG: Effect of elevated glucose on endothelin-induced store-operated and non-store-operated calcium influx in renal mesangial cells. J Am Soc Nephrol. 11:1225–1235. 2000.PubMed/NCBI

7 

Whiteside CI, Hurst RD and Stevanovic ZS: Calcium signaling and contractile response of diabetic glomerular mesangial cells. Kidney Int. 51(Suppl): S28–S33. 1995.PubMed/NCBI

8 

Wu JP, Zhang W, Wu F, et al: Honokiol: an effective inhibitor of high-glucose-induced upregulation of inflammatory cytokine production in human renal mesangial cells. Inflamm Res. 59:1073–1079. 2010. View Article : Google Scholar : PubMed/NCBI

9 

Hsu YJ, Hoenderop JG and Bindels RJ: TRP channels in kidney disease. Biochim Biophys Acta. 1772:928–936. 2007. View Article : Google Scholar : PubMed/NCBI

10 

Smyth JT, Hwang SY, Tomita T, DeHaven WI, Mercer JC and Putney JW: Activation and regulation of store-operated calcium entry. J Cell Mol Med. 14:2337–2349. 2010. View Article : Google Scholar : PubMed/NCBI

11 

Nilius B and Owsianik G: The transient receptor potential family of ion channels. Genome Biol. 12:2182011. View Article : Google Scholar : PubMed/NCBI

12 

Dietrich A and Gudermann T: Trpc6. Handb Exp Pharmacol. 125–141. 2007. View Article : Google Scholar

13 

Ma R, Du J, Sours S and Ding M: Store-operated Ca2+ channel in renal microcirculation and glomeruli. Exp Biol Med (Maywood). 231:145–153. 2006.

14 

Möller CC, Wei C, Altintas MM, et al: Induction of TRPC6 channel in acquired forms of proteinuric kidney disease. J Am Soc Nephrol. 18:29–36. 2007.PubMed/NCBI

15 

Graham S, Ding M, Sours-Brothers S, Yorio T, Ma JX and Ma R: Downregulation of TRPC6 protein expression by high glucose, a possible mechanism for the impaired Ca2+ signaling in glomerular mesangial cells in diabetes. Am J Physiol Renal Physiol. 293:F1381–F1390. 2007. View Article : Google Scholar : PubMed/NCBI

16 

Danesh FR, Sadeghi MM, Amro N, et al: 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: Implications for diabetic nephropathy. Proc Natl Acad Sci USA. 99:8301–8305. 2002. View Article : Google Scholar

17 

Banday AA, Fazili FR and Lokhandwala MF: Oxidative stress causes renal dopamine D1 receptor dysfunction and hypertension via mechanisms that involve nuclear factor-kappaB and protein kinase C. J Am Soc Nephrol. 18:1446–1457. 2007. View Article : Google Scholar : PubMed/NCBI

18 

Forbes JM, Coughlan MT and Cooper ME: Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes. 57:1446–1454. 2008. View Article : Google Scholar : PubMed/NCBI

19 

Ha H and Lee HB: Reactive oxygen species as glucose signaling molecules in mesangial cells cultured under high glucose. Kidney Int Suppl. 77:S19–S25. 2000. View Article : Google Scholar : PubMed/NCBI

20 

Hool LC and Corry B: Redox control of calcium channels: from mechanisms to therapeutic opportunities. Antioxid Redox Signal. 9:409–435. 2007. View Article : Google Scholar : PubMed/NCBI

21 

Gill PS and Wilcox CS: NADPH oxidases in the kidney. Antioxid Redox Signal. 8:1597–1607. 2006. View Article : Google Scholar

22 

Babior BM, Lambeth JD and Nauseef W: The neutrophil NADPH oxidase. Arch Biochem Biophys. 397:342–344. 2002. View Article : Google Scholar : PubMed/NCBI

23 

Nauseef WM: Biological roles for the NOX family NADPH oxidases. J Biol Chem. 283:16961–16965. 2008. View Article : Google Scholar : PubMed/NCBI

24 

Block K, Eid A, Griendling KK, Lee DY, Wittrant Y and Gorin Y: Nox4 NAD(P)H oxidase mediates Src-dependent tyrosine phosphorylation of PDK-1 in response to angiotensin II: role in mesangial cell hypertrophy and fibronectin expression. J Biol Chem. 283:24061–24076. 2008. View Article : Google Scholar : PubMed/NCBI

25 

Koyasu S: The role of PI3K in immune cells. Nat Immunol. 4:313–319. 2003. View Article : Google Scholar : PubMed/NCBI

26 

Shiojima I and Walsh K: Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res. 90:1243–1250. 2002. View Article : Google Scholar : PubMed/NCBI

27 

Kim SY, Park KH, Gul R, Jang KY and Kim UH: Role of kidney ADP-ribosyl cyclase in diabetic nephropathy. Am J Physiol Renal Physiol. 296:F291–F297. 2009. View Article : Google Scholar : PubMed/NCBI

28 

Kim SY, Gul R, Rah SY, et al: Molecular mechanism of ADP-ribosyl cyclase activation in angiotensin II signaling in murine mesangial cells. Am J Physiol Renal Physiol. 294:F982–F989. 2008. View Article : Google Scholar : PubMed/NCBI

29 

Sousa LP, Carmo AF, Rezende BM, et al: Cyclic AMP enhances resolution of allergic pleurisy by promoting inflammatory cell apoptosis via inhibition of PI3K/Akt and NF-kappaB. Biochem Pharmacol. 78:396–405. 2009. View Article : Google Scholar : PubMed/NCBI

30 

Li J and Bertram JF: Review: Endothelial-myofibroblast transition, a new player in diabetic renal fibrosis. Nephrology (Carlton). 15:507–512. 2010. View Article : Google Scholar : PubMed/NCBI

31 

Yang WS, Seo JW, Han NJ, et al: High glucose-induced NF-kappaB activation occurs via tyrosine phosphorylation of IkappaBalpha in human glomerular endothelial cells: involvement of Syk tyrosine kinase. Am J Physiol Renal Physiol. 294:F1065–F1075. 2008. View Article : Google Scholar

32 

Nitti M, Furfaro AL, Patriarca S, et al: Human mesangial cells resist glycoxidative stress through an antioxidant response. Int J Mol Med. 27:213–219. 2011.PubMed/NCBI

33 

Wang XW, Tan BZ, Sun M, Ho B and Ding JL: Thioredoxin-like 6 protects retinal cell line from photooxidative damage by upregulating NF-kappaB activity. Free Radic Biol Med. 45:336–344. 2008. View Article : Google Scholar : PubMed/NCBI

34 

Ren S, Zhang H, Mu Y, Sun M and Liu P: Pharmacological effects of Astragaloside IV: a literature review. J Tradit Chin Med. 33:413–416. 2013. View Article : Google Scholar : PubMed/NCBI

35 

You H, Lu Y, Gui D, Peng A, Chen J and Gu Y: Aqueous extract of Astragali Radix ameliorates proteinuria in adriamycin nephropathy rats through inhibition of oxidative stress and endothelial nitric oxide synthase. J Ethnopharmacol. 134:176–182. 2011. View Article : Google Scholar

36 

Motomura K, Fujiwara Y, Kiyota N, et al: Astragalosides isolated from the root of astragalus radix inhibit the formation of advanced glycation end products. J Agric Food Chem. 57:7666–7672. 2009. View Article : Google Scholar : PubMed/NCBI

37 

Wang O, Cai K, Pang S, et al: Mechanisms of glucose-induced expression of pancreatic-derived factor in pancreatic beta-cells. Endocrinology. 149:672–680. 2008. View Article : Google Scholar : PubMed/NCBI

38 

Jeong SI, Kim SJ, Kwon TH, Yu KY and Kim SY: Schizandrin prevents damage of murine mesangial cells via blocking NADPH oxidase-induced ROS signaling in high glucose. Food Chem Toxicol. 50:1045–1053. 2012. View Article : Google Scholar : PubMed/NCBI

39 

Wu F and Chen X: A review of pharmacological study on Astragalus membranaceus(Fisch.) Bge. Zhong Yao Cai. 27:232–234. 2004.(In Chinese).

40 

Gui D, Guo Y, Wang F, et al: Astragaloside IV, a novel antioxidant, prevents glucose-induced podocyte apoptosis in vitro and in vivo. PloS one. 7:e398242012. View Article : Google Scholar : PubMed/NCBI

41 

Gui D, Huang J, Liu W, Guo Y, Xiao W and Wang N: Astragaloside IV prevents acute kidney injury in two rodent models by inhibiting oxidative stress and apoptosis pathways. Apoptosis. 18:409–422. 2013. View Article : Google Scholar : PubMed/NCBI

42 

Cao LL, Li WZ, Si XL, Sun L and Li WP: Protective effect and mechanism of astragaloside IV on oxidative stress injury of mesangial cells. Zhongguo Zhong Yao Za Zhi. 38:725–730. 2013.(In Chinese).

43 

Ha H, Hwang IA, Park JH and Lee HB: Role of reactive oxygen species in the pathogenesis of diabetic nephropathy. Diabetes Res Clin Pract. 82(Suppl 1): S42–S45. 2008. View Article : Google Scholar : PubMed/NCBI

44 

Hodgkinson AD, Bartlett T, Oates PJ, Millward BA and Demaine AG: The response of antioxidant genes to hyperglycemia is abnormal in patients with type 1 diabetes and diabetic nephropathy. Diabetes. 52:846–851. 2003. View Article : Google Scholar : PubMed/NCBI

45 

Babior BM: NADPH oxidase. Curr Opin Immunol. 16:42–47. 2004. View Article : Google Scholar

46 

Gorin Y, Ricono JM, Kim NH, Bhandari B, Choudhury GG and Abboud HE: Nox4 mediates angiotensin II-induced activation of Akt/protein kinase B in mesangial cells. Am J Physiol Renal Physiol. 285:F219–F229. 2003.PubMed/NCBI

47 

Devaraj S, Cheung AT, Jialal I, et al: Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes. 56:2790–2796. 2007. View Article : Google Scholar : PubMed/NCBI

48 

Gruden G, Setti G, Hayward A, et al: Mechanical stretch induces monocyte chemoattractant activity via an NF-kappaB-dependent monocyte chemoattractant protein-1-mediated pathway in human mesangial cells: inhibition by rosiglitazone. J Am Soc Nephrol. 16:688–696. 2005. View Article : Google Scholar

49 

Iwamoto M, Mizuiri S, Arita M and Hemmi H: Nuclear factor-kappaB activation in diabetic rat kidney: evidence for involvement of P-selectin in diabetic nephropathy. Tohoku J Exp Med. 206:163–171. 2005. View Article : Google Scholar : PubMed/NCBI

50 

Bäumer AT, Ten Freyhaus H, Sauer H, et al: Phosphatidylinositol 3-kinase-dependent membrane recruitment of Rac-1 and p47phox is critical for alpha-platelet-derived growth factor receptor-induced production of reactive oxygen species. J Biol Chem. 283:7864–7876. 2008.PubMed/NCBI

51 

Graham S, Gorin Y, Abboud HE, et al: Abundance of TRPC6 protein in glomerular mesangial cells is decreased by ROS and PKC in diabetes. Am J Physiol Cell Physiol. 301:C304–C315. 2011. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Sun L, Li W, Li W, Xiong L, Li G and Ma R: Astragaloside IV prevents damage to human mesangial cells through the inhibition of the NADPH oxidase/ROS/Akt/NF‑κB pathway under high glucose conditions. Int J Mol Med 34: 167-176, 2014.
APA
Sun, L., Li, W., Li, W., Xiong, L., Li, G., & Ma, R. (2014). Astragaloside IV prevents damage to human mesangial cells through the inhibition of the NADPH oxidase/ROS/Akt/NF‑κB pathway under high glucose conditions. International Journal of Molecular Medicine, 34, 167-176. https://doi.org/10.3892/ijmm.2014.1741
MLA
Sun, L., Li, W., Li, W., Xiong, L., Li, G., Ma, R."Astragaloside IV prevents damage to human mesangial cells through the inhibition of the NADPH oxidase/ROS/Akt/NF‑κB pathway under high glucose conditions". International Journal of Molecular Medicine 34.1 (2014): 167-176.
Chicago
Sun, L., Li, W., Li, W., Xiong, L., Li, G., Ma, R."Astragaloside IV prevents damage to human mesangial cells through the inhibition of the NADPH oxidase/ROS/Akt/NF‑κB pathway under high glucose conditions". International Journal of Molecular Medicine 34, no. 1 (2014): 167-176. https://doi.org/10.3892/ijmm.2014.1741
Copy and paste a formatted citation
x
Spandidos Publications style
Sun L, Li W, Li W, Xiong L, Li G and Ma R: Astragaloside IV prevents damage to human mesangial cells through the inhibition of the NADPH oxidase/ROS/Akt/NF‑κB pathway under high glucose conditions. Int J Mol Med 34: 167-176, 2014.
APA
Sun, L., Li, W., Li, W., Xiong, L., Li, G., & Ma, R. (2014). Astragaloside IV prevents damage to human mesangial cells through the inhibition of the NADPH oxidase/ROS/Akt/NF‑κB pathway under high glucose conditions. International Journal of Molecular Medicine, 34, 167-176. https://doi.org/10.3892/ijmm.2014.1741
MLA
Sun, L., Li, W., Li, W., Xiong, L., Li, G., Ma, R."Astragaloside IV prevents damage to human mesangial cells through the inhibition of the NADPH oxidase/ROS/Akt/NF‑κB pathway under high glucose conditions". International Journal of Molecular Medicine 34.1 (2014): 167-176.
Chicago
Sun, L., Li, W., Li, W., Xiong, L., Li, G., Ma, R."Astragaloside IV prevents damage to human mesangial cells through the inhibition of the NADPH oxidase/ROS/Akt/NF‑κB pathway under high glucose conditions". International Journal of Molecular Medicine 34, no. 1 (2014): 167-176. https://doi.org/10.3892/ijmm.2014.1741
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team